Deutsche Bank analyst Justin Bowers initiated coverage of Thermo Fisher with a Buy rating and $620 price target. The analyst launched coverage of 10 life science tools companies that have "outsized exposure" to the biopharma end market. The stocks that outperform in 2023 "will provide downside protection or are idiosyncratic," Bowers tells investors in a research note. He recommends "captains of culture" Danaher (DHR) and Thermo Fisher Scientific (TMO) for more defensive posturing. Buy-rated rated Maravai Lifesciences (MRVI), Bio-Techne (TECH) and 10X Genomics (TXG) offer novel technology and have embedded optionality, Bowers tells investors in a research note. His Hold-rated names reflect wanting better entry points andconviction in consensus estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TMO:
- Thermo Fisher Stock (NYSE:TMO): Is Its Superb Quality Worth the Price?
- Tecogen appoints Albertine to board of directors
- Thermo Fisher initiated with an Outperform at RBC Capital
- Thermo Fisher price target lowered to $570 from $575 at Barclays
- Follow the Hedge Fund: Top Manager Ray Dalio Placed Big Bucks on These 5 Stocks